GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (FRA:HQ1) » Definitions » Gross Margin %

Oruka Therapeutics (FRA:HQ1) Gross Margin % : 0.00% (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Oruka Therapeutics's Gross Profit for the three months ended in Sep. 2024 was €0.00 Mil. Oruka Therapeutics's Revenue for the three months ended in Sep. 2024 was €0.00 Mil. Therefore, Oruka Therapeutics's Gross Margin % for the quarter that ended in Sep. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Oruka Therapeutics's Gross Margin % or its related term are showing as below:


FRA:HQ1's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.58
* Ranked among companies with meaningful Gross Margin % only.

Oruka Therapeutics had a gross margin of N/A% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Oruka Therapeutics was 0.00% per year.


Oruka Therapeutics Gross Margin % Historical Data

The historical data trend for Oruka Therapeutics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Gross Margin % Chart

Oruka Therapeutics Annual Data
Trend
Gross Margin %

Oruka Therapeutics Quarterly Data
Mar24 Jun24 Sep24
Gross Margin % - - -

Competitive Comparison of Oruka Therapeutics's Gross Margin %

For the Biotechnology subindustry, Oruka Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oruka Therapeutics's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oruka Therapeutics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Oruka Therapeutics's Gross Margin % falls into.



Oruka Therapeutics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Oruka Therapeutics's Gross Margin for the fiscal year that ended in . 20 is calculated as

Gross Margin % (A: . 20 )=Gross Profit (A: . 20 ) / Revenue (A: . 20 )
=0 /
=(Revenue - Cost of Goods Sold) / Revenue
=( - ) /
=N/A %

Oruka Therapeutics's Gross Margin for the quarter that ended in Sep. 2024 is calculated as


Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Oruka Therapeutics  (FRA:HQ1) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Oruka Therapeutics had a gross margin of N/A% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Oruka Therapeutics Gross Margin % Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Oruka Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
Address
221 Crescent Street, Building 23, Suite 105, Waltham, MA, USA, 02453
Website
Oruka Therapeutics Inc is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. It is to offer patients suffering from chronic skin diseases like plaque psoriasis.

Oruka Therapeutics Headlines

No Headlines